Urgency as an Endpoint in Irritable Bowel Syndrome

BACKGROUND: The choice of endpoints is crucial for proper evaluation of agents in clinical trials of irritable bowel syndrome (IBS). In a recently published draft guidance for IBS from the United States Food and Drug Administration (FDA), urgency was not considered an appropriate primary endpoint. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangel, Allen W., Wang, Jianmin, Sherrill, Beth, Gnanasakthy, Ari, Ervin, Claire, Fehnel, Sheri E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139794/
https://www.ncbi.nlm.nih.gov/pubmed/27957006
http://dx.doi.org/10.4021/gr283e

Ejemplares similares

Ejemplares similares